Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Jul 26:2022:3835545.
doi: 10.1155/2022/3835545. eCollection 2022.

Transnasal High-Flow Oxygen Therapy versus Noninvasive Positive Pressure Ventilation in the Treatment of COPD with Type II Respiratory Failure: A Meta-Analysis

Wei Liu  1 , Mingli Zhu  2 , Liuqin Xia  2 , Xiangying Yang  2 , Pei Huang  2 , Yanming Sun  2 , Ye Shen  2 , Jianping Ma  2
Affiliations
Meta-Analysis

Transnasal High-Flow Oxygen Therapy versus Noninvasive Positive Pressure Ventilation in the Treatment of COPD with Type II Respiratory Failure: A Meta-Analysis

Wei Liu et al. Comput Math Methods Med. .

Retraction in

Abstract

Objective: To compare the safety and efficacy of transnasal high-flow oxygen therapy (HFNT) and noninvasive positive pressure ventilation (NIV) in the treatment of chronic obstructive pulmonary disease (COPD) with type II respiratory failure.

Methods: PubMed, the Cochrane Library, Embase, CBM, CNKI, and other databases were searched for randomized controlled trials (RCTS) on the efficacy of HFNT and NIV in the treatment of COPD. Meta-analysis was conducted using RevMan 5.3 software after two researchers screened literatures, extracted data, and evaluated the methodological quality of the included studies according to inclusion and exclusion criteria.

Results: A total of 948 patients were included in 12 RCTS. Comprehensive analysis results showed that the HFNC group had higher levels of 12 h-PAO2, 48 h-PACO2 and, 48 h-pH than the NIV group, and the differences were statistically significant (P < 0.05). There were no significant differences in 24 h-PAO2 and 72 h-PAO2, 12 h-PACO2, 24 h-PACO2 and 72 h-PACO2, 24 h-pH, 48 h-pH, and 72 h-pH between the two groups after treatment (P > 0.05).

Conclusions: Compared with NIV, HFNC does not increase the treatment failure rate in COPD patients with type II respiratory failure, and HFNC has better comfort and tolerance, which is a new potential respiratory support treatment for COPD patients with type II respiratory failure.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Risk of bias summary.
Figure 2
Figure 2
Comparison of 12 h-PAO2 after treatment between the HFNC group and NIV group.
Figure 3
Figure 3
Comparison of 12 h-PaCO2 after treatment between the HFNC group and NIV group.
Figure 4
Figure 4
Comparison of 24 h-PAO2 after treatment between the HFNC group and NIV group.
Figure 5
Figure 5
Comparison of 24 h-PACO2 after treatment between the HFNC group and NIV group.
Figure 6
Figure 6
Comparison of 24 h-pH after treatment between the HFNC group and NIV group.
Figure 7
Figure 7
Comparison of 48 h-PAO2 after treatment between the HFNC group and NIV group.
Figure 8
Figure 8
Comparison of 48 h-PACO2 after treatment between the HFNC group and NIV group.
Figure 9
Figure 9
Comparison of 48 h-pH after treatment between the HFNC group and NIV group.
Figure 10
Figure 10
Comparison of 72 h-PAO2 after treatment between the HFNC group and NIV group.
Figure 11
Figure 11
Comparison of 72 h-PaCO2 after treatment between the HFNC group and NIV group.
Figure 12
Figure 12
Comparison of 72 h-pH after treatment between the HFNC group and NIV group.
Figure 13
Figure 13
Funnel plot.
See this image and copyright information in PMC

References

    1. Labaki W. W., Rosenberg S. R. Chronic obstructive pulmonary disease. Annals of Internal Medicine . 2020;173(3) doi: 10.7326/AITC202008040. - DOI - PubMed
    1. Cook S., Eggen A. E., Hopstock L. A., et al. Chronic obstructive pulmonary disease (COPD) in population studies in Russia and Norway: comparison of prevalence, awareness and management. International Journal of Chronic Obstructive Pulmonary Disease . 2021;16:1353–1368. doi: 10.2147/COPD.S292472. - DOI - PMC - PubMed
    1. Sun J., Li Y., Ling B., et al. High flow nasal cannula oxygen therapy versus non-invasive ventilation for chronic obstructive pulmonary disease with acute-moderate hypercapnic respiratory failure: an observational cohort study. International Journal of Chronic Obstructive Pulmonary Disease . 2019;14:1229–1237. doi: 10.2147/COPD.S206567. - DOI - PMC - PubMed
    1. Kim D. K., Lee J., Park J. H., Yoo K. H. What can we apply to manage acute exacerbation of chronic obstructive pulmonary disease with acute respiratory failure? Tuberc Respir Dis (Seoul). . 2018;81(2):99–105. doi: 10.4046/trd.2017.0094. - DOI - PMC - PubMed
    1. Hong S., Tian Y., Li Y., Qiao L. Meta-analysis of clinical efficacy of Helmet non-invasive ventilation and oxygen therapy on patients with hypoxemic respiratory failure. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue . 2019;31(9):1118–1122. doi: 10.3760/cma.j.issn.2095-4352.2019.09.012. - DOI - PubMed

MeSH terms